Overview
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
Status:
Completed
Completed
Trial end date:
2006-08-01
2006-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months durationPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Cardiome Pharma
Correvio International Sarl
Criteria
Inclusion Criteria (partial list):- Subjects must have sustained, symptomatic atrial fibrillation for greater than 72
hours and less than 6 months duration
- Subjects must have adequate anticoagulant therapy
Exclusion Criteria (partial list):
- Subjects may not have Class III or Class IV congestive heart failure
- Subjects may not have uncorrected electrolyte imbalance